ChemInform Abstract: Synthesis of 2-Amino-6-(2- [18F] fluoro-pyridine-4-ylmethoxy)-9-(octyl-β-D-glucosyl)-purine: A Novel Radioligand for Positron Emission Tomography Studies of the O6-Methylguanine-DNA Methyltransferase (MGMT) Status of Tumor Tissue.

ChemInform ◽  
2010 ◽  
Vol 33 (50) ◽  
pp. no-no
Author(s):  
Ralf Schirrmacher ◽  
Ute Muehlhausen ◽  
Bjoern Waengler ◽  
Esther Schirrmacher ◽  
Jost Reinhard ◽  
...  
Keyword(s):  
Positron Emission Tomography ◽  
Dna Methyltransferase ◽  
Tumor Tissue ◽  
Emission Tomography ◽  
Methylguanine Dna Methyltransferase ◽  
Positron Emission

Positron Emission Tomography As an Imaging Biomarker

2006 ◽  
Vol 24 (20) ◽  
pp. 3282-3292 ◽  
Author(s):  
Wolfgang A. Weber
Keyword(s):  
Positron Emission Tomography ◽  
Tumor Tissue ◽  
Cytotoxic Agents ◽  
Emission Tomography ◽  
Imaging Biomarker ◽  
Treatment Regimens ◽  
Quantitative Studies ◽  
Phase Ii Studies ◽  
Positron Emission ◽  
The Individual

Positron emission tomography (PET) allows noninvasive, quantitative studies of various biologic processes in the tumor tissue. By using PET, investigators can study the pharmacokinetics of anticancer drugs, identify various therapeutic targets and monitor the inhibition of these targets during therapy. Furthermore, PET provides various markers to assess tumor response early in the course of therapy. A significant number of studies have now shown that changes in tumor glucose utilization during the first weeks of chemotherapy are significantly correlated with patient outcome. These data suggest that PET may be used as a sensitive test to assess the activity of new cytotoxic agents in phase II studies. Furthermore, early identification of nonresponding tumors provides the opportunity to adjust treatment regimens according to the individual chemosensitivity of the tumor tissue. However, further prospective and randomized validation of PET is still required before PET controlled chemotherapy can be used in clinical practice.

Predictive Impact of 2-18Fluoro-2-Deoxy-d-Glucose Positron Emission Tomography for Residual Postchemotherapy Masses in Patients With Bulky Seminoma

2001 ◽  
Vol 19 (17) ◽  
pp. 3740-3744 ◽  
Author(s):  
Maria De Santis ◽  
Carsten Bokemeyer ◽  
Alexander Becherer ◽  
Franz Stoiber ◽  
Karin Oechsle ◽  
...  
Keyword(s):  
Positron Emission Tomography ◽  
Fdg Pet ◽  
Tumor Tissue ◽  
Emission Tomography ◽  
Viable Tumor ◽  
Positron Emission ◽  
Viable Tumor Tissue ◽  
Pet Scans ◽  
Residual Lesions

PURPOSE: To establish the predictive potential of 2-18fluoro-2-deoxy-d-glucose positron emission tomography (FDG PET) for detecting viable tumor tissue in residual postchemotherapy masses of seminoma patients. PATIENTS AND METHODS: In this prospective multicenter trial, results of FDG PET studies in seminoma patients with postchemotherapy masses ≥ 1 cm were correlated with either the histology of the resected lesion or the clinical outcome on follow-up without resection. Negative PET scans of residual lesions that were devoid of viable tumor tissue on resection or disappeared, shrunk, or remained stable in size for at least 2 years were rated as true-negative (TN). Positive scans without histologic or clinical evidence of tumor tissue were classified as false-positive. In patients with histologically positive or progressive lesions, positive PET scans were defined as true-positive (TP) and negative scans, false-negative (FN). RESULTS: Thirty-seven PET scans of 33 patients were assessable at a median follow-up time of 23 months (range, 2 to 46 months). Histologic data were available from nine patients who had undergone resection. Twenty-eight patients were followed-up clinically and radiologically. Twenty-eight scans were TN, eight were TP, and one was FN. All 14 residual lesions more than 3 cm and 22 (96%) of the 23 ≤ 3 cm were correctly predicted by FDG PET. The specificity (100%; 95% confidence interval [CI], 87.7% to 100%), sensitivity (89%; 95% CI, 51.7% to 99.7%), positive predictive value (100%), and the negative predictive value (97%) of FDG PET were superior to data obtained by assessing residual tumor size (≤ or > 3 cm). CONCLUSION: FDG PET is a clinically useful predictor of viable tumor in postchemotherapy residuals of pure seminoma, especially those greater than 3 cm.

Identification of tumor tissue by FTIR spectroscopy in combination with positron emission tomography

2002 ◽  
Vol 28 (1) ◽  
pp. 103-110 ◽  
Author(s):  
Tom Richter ◽  
Gerald Steiner ◽  
Mario H. Abu-Id ◽  
Reiner Salzer ◽  
Ralf Bergmann ◽  
...  
Keyword(s):  
Positron Emission Tomography ◽  
Ftir Spectroscopy ◽  
Tumor Tissue ◽  
Emission Tomography ◽  
Positron Emission

Multimodal metabolic imaging of cerebral gliomas: positron emission tomography with [18F]fluoroethyl-l-tyrosine and magnetic resonance spectroscopy

2005 ◽  
Vol 102 (2) ◽  
pp. 318-327 ◽  
Author(s):  
Frank Willi Floeth ◽  
Dirk Pauleit ◽  
Hans-Jörg Wittsack ◽  
Karl Josef Langen ◽  
Guido Reifenberger ◽  
...  
Keyword(s):  
Positron Emission Tomography ◽  
Mr Imaging ◽  
Mr Spectroscopy ◽  
Tumor Tissue ◽  
Emission Tomography ◽  
Content Type ◽  
Fet Pet ◽  
Positron Emission ◽  
Diffuse Gliomas ◽  
Fine Print

Object. The purpose of this study was to determine the predictive value of [18F]fluoroethyl-l-tyrosine (FET)—positron emission tomography (PET) and magnetic resonance (MR) spectroscopy for tumor diagnosis in patients with suspected gliomas. Methods. Both FET-PET and MR spectroscopy analyses were performed in 50 consecutive patients with newly diagnosed intracerebral lesions supposed to be diffuse gliomas on contrast-enhanced MR imaging. Lesion/brain ratios of FET uptake greater than 1.6 were considered positive, that is, indicative of tumor. Results of MR spectroscopy were considered positive when N-acetylaspartate (NAA) was decreased in conjunction with an absolute increase of choline (Cho) and an NAA/Cho ratio of 0.7 or less. An FET lesion/brain ratio, an NAA/Cho ratio, and signal abnormalities on MR images were compared with histological findings in neuronavigated biopsy specimens. The FET lesion/brain ratio and the NAA/Cho ratio were identified as significant independent predictors for the histological identification of tumor tissue. The accuracy in distinguishing neoplastic from nonneoplastic tissue could be increased from 68% with the use of MR imaging alone to 97% with MR imaging in conjunction with FET-PET and MR spectroscopy. Sensitivity and specificity for tumor detection were 100 and 81% for MR spectroscopy and 88 and 88% for FET-PET, respectively. Results of histological studies did not reveal tumor tissue in any of the lesions that were negative on FET-PET and MR spectroscopy. In contrast, a tumor diagnosis was made in 97% of the lesions that were positive with both methods. Conclusions. In patients with intracerebral lesions supposed to be diffuse gliomas on MR imaging, FET-PET and MR spectroscopy analyses markedly improved the diagnostic efficacy of targeted biopsies.

Sign in / Sign up

Export Citation Format

Share Document